Drug Crisis: Will US Pricing Policy Harm Israel?
Published
The drug pricing policy led by the government of US President Donald Trump may also affect Israel. Kobi Tzoref, CEO of Pharma Israel, warns that patients in Israel are already feeling the consequences of the situation.
The reason for concern is that international pharmaceutical companies may change their plans. When prices in the American market change, companies may decide to launch new drugs in certain countries later, or not to launch them at all. Therefore, the situation in the United States can affect the availability of drugs in other markets.
According to Tzoref, there is a fear that international companies will reduce their activity in Israel. If this happens, patients may have to wait longer for new drugs, and certain medications may become less available. Tzoref emphasizes that the issue is especially important for the Israeli healthcare system.
The issue remains open, and the situation may change later in the year. It is worth following the decisions of pharmaceutical companies and regulatory bodies in Israel, in order to understand how American policy affects patients and doctors in the country.
Sources: YNET
More Israel news
- Israel and France Explore New Approaches to Mental Health Care
- Sudden Facial Paralysis and Diabetes: What a New Israeli Study Shows
- A U.S. Medical Delegation Visited Laniado Hospital in Netanya
- A Special Crossing Over Route 6: A Bridge for Wildlife
- Revolut Receives Conditional License to Establish a Bank in Israel
- Ministry of Health Cancels Water Boiling Order in Kfar Chabad
- Eisenkot and opposition leaders agree on candidates for key Knesset positions
- Exiled Iranian Prince: Iran Is Likely to Use Nuclear Weapons Against Israel